Feed TRMED.OL
Summary
51 / 100 · Bulios Score
Valuation 54Growth 100Profitability -Quality 2Debt 84Stability 19
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- It passes only 1 of the 9 points of the Piotroski financial health test.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedIs it growing?
Yes, fastRevenue (NOK)
2021202220232024202520262027
Diluted EPS (NOK)
2021202220232024202520262027
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Debt is a burdenCash and short-term investments 59.9M kr
Debt 242.2M kr
Free cash flow over 12 months -236.7M kr
Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail